Zenas BioPharma, Inc. presents a perplexing valuation scenario. The market’s pricing, significantly above its DCF value, suggests a disconnect between expectations and financial reality. With a Forward P/E of -25.51 and an Earnings Yield of -27.62%, the company is priced for a future turnaround that its current metrics do not support. The Altman Z-score of -1.31 signals distress, raising red flags about its financial stability. Investors should be wary of the speculative nature of this stock, given its current financial health.